Akcea Therapeutics (NASDAQ: AKCA) has recently received a number of price target changes and ratings updates: 3/19/2018 – Akcea Therapeutics had its “market perform” rating reaffirmed by analysts at Wells Fargo. They now have a $20.00 price target on the stock. 3/19/2018 – Akcea Therapeutics was upgraded by analysts at Zacks Investment Research from a […]
